CVOTs cardiovascular outcome trials, T2DM type 2 diabetes mellitus, GLP-1RAs GLP-1 receptor agonists, HbA1c glycated hemoglobin, ACS acute coronary syndrome, OAD oral antidiabetic drugs, eGFR estimated glomerular filtration rate, UACR urine albumin-creatinine ratio, CVD cardiovascular disease, BMI body mass index, T1DM type 1 diabetes mellitus, DPP-4i DPP-4 inhibitor, HR hazard ratio, CI confidence interval, HF heart failure Outside of those major clinical trials, a nationwide retrospective study in Taiwan, China, evaluated the effects of DPP-4i in elderly patients with T2DM relative to cardiovascular outcomes
[1] [2] It represents a novel class of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, making it the first dual incretin receptor agonist available in clinical practice
It is often a sign that the supplement is either not being absorbed well or is irritating the stomach lining due to its formulation
Cellular Compatibility: Because the liposome is made of the same material as your cell walls, it can merge with the cell membrane, delivering the nutrient directly into the cell
S.et al (2024)
